MIRM News and Press, Mirum Pharmaceuticals Inc. From 02/25/26

2026-02-25 17:51:32 ET Image source: The Motley Fool. Wednesday, Feb. 25, 2026, at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-25 16:11:54 ET More on Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. (MIRM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Mirum Pharmaceuticals: Rich In 2025, Richer (In Promise) In 2026? I Believe So Mirum: Maintaining Buy Rating O...

- 2025 net product sales of $521 million - 2026 expected global net product sales of $630 million to $650 million - Volixibat VISTAS study in PSC topline data expected Q2 2026 - LIVMARLI ® EXPAND study in additional cholestatic pruritus settings topline data exp...

2026-02-25 13:26:50 ET According to a Securities and Exchange Commission (SEC) filing dated February 09, 2026, Penn Capital Management Company, LLC established a new position in ACM Research, Inc. (NASDAQ:ACMR) during the fourth quarter of 2025, acquiring 435,843 shares. The positio...

HCI Group Inc. (HCI) is expected to report $4.87 for Q4 2025 XPEL Inc. (XPEL) is expected to report $0.43 for Q4 2025 Oversea-Chinese Banking Corporation Limited ADR (OVCHY) is expected to report $0.56 for Q4 2025 UMH Properties Inc. (UMH) is expected to report $0.24 for Q4 2025 I...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will report fourth quarter and year-end 2025 financial results on February 25, 2026. Mirum will also host a conference call to discuss the fourth quarter and year-end 2025 financial results and recent corporate progress. Confe...

2026-02-17 17:04:00 ET from RBC Capital issued a price target of $130.00 for MIRM on 2026-02-17 21:23:17. The adjusted price target was set to $130.00. At the time of the announcement, MIRM was trading at $102.83. The overall price target consensus is at $110.67 with hig...

2026-02-17 16:15:03 ET RBC Capital analyst issues OUTPERFORM recommendation for MIRM on February 17, 2026 09:23PM ET. MIRM was trading at $102.83 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Strong...

- Tablet authorization builds upon established use of LIVMARLI oral solution in Canada Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized the tablet formulation of LIVMARLI ® (maralixibat) for the tr...

- Authorization includes oral solution and tablet formulation to support flexible dosing Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that Health Canada has authorized LIVMARLI ® (maralixibat) oral solution and tablet formu...